MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/gme.0000000000002854

Медицинская библиотека · Menopause (New York, N.Y.) · 2026

Weight loss interventions and sexual function in midlife women: the emerging role of glucagon-like peptide-1 receptor agonists.

Castaneda Regina, Sepulveda Diego, Hurtado Andrade Maria D, Shufelt Chrisandra L, Faubion Stephanie S

СтатьяПеревод пока не подготовлен

Аннотация

IMPORTANCE AND

OBJECTIVE

Sexual health is a multidimensional aspect of women's well-being. It is particularly vulnerable during midlife, when the physiological and psychosocial changes of the menopause transition intersect with the growing burden of obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as highly effective pharmacologic treatments for obesity, yet their effects on female sexual function remain largely uncharacterized. This review aims to discuss the interplay among obesity, midlife, obesity treatments, and female sexual health, with a focused synthesis of available evidence on GLP-1-based therapies and sexual outcomes in women.

METHODS

This narrative review synthesizes preclinical studies, case reports, observational data, and clinical trials identified through PubMed searches from inception through March 2026, examining female sexual function in the context of obesity, the menopause transition, obesity treatments, and GLP-1 receptor agonist therapy.

DISCUSSION AND

CONCLUSION

Obesity impairs female sexual function through hormonal, vascular, and psychosocial mechanisms. Accordingly, lifestyle interventions and bariatric surgery have demonstrated meaningful improvements in sexual function. In contrast, GLP-1 receptor agonists, despite conferring substantial weight loss and favorable metabolic effects, may paradoxically suppress sexual desire and arousal through central neuroendocrine mechanisms, including the modulation of dopaminergic reward and serotonergic signaling. While emerging case reports and preclinical data support this concern, systematic clinical evidence remains limited, highlighting the need for prospective studies with longitudinal sexual function endpoints. In this context, clinicians should proactively assess sexual function before and during GLP-1 therapy using validated instruments and integrate sexual health into comprehensive obesity care for midlife women.

Для цитирования: Castaneda Regina, Sepulveda Diego, Hurtado Andrade Maria D, Shufelt Chrisandra L, Faubion Stephanie S. Weight loss interventions and sexual function in midlife women: the emerging role of glucagon-like peptide-1 receptor agonists.. Menopause (New York, N.Y.). 2026. DOI: 10.1097/gme.0000000000002854.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.